Brainstorm Cell Therapeutics Faces Securities Class Action

Rosen Law Firm is urging Brainstorm Cell Therapeutics Inc. investors to participate in a securities class action lawsuit due to alleged false and misleading statements by the company's defendants. The firm emphasizes its experience in securities class action settlements and highlights the severity of the U.S. Food and Drug Administration's refusal to file letter and concealed risks associated with the submission of the biologics license application, leading to investor damages.